Biogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow BIIB
Biogen Inc. (BIIB) EV/FCF
As of 16 October 2026, Biogen Inc. (BIIB) trades at a EV/FCF of 15.9×. Over the past ten years it has ranged from −1,928× (April 2015) to 42.2× (October 2023); the current reading is higher than 57% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 14.0× | 44.05% |
| FY2024 | 9.7× | (73.01%) |
| FY2023 | 36.0× | 51.30% |
| FY2022 | 23.8× | 109.17% |
| FY2021 | 11.4× | (5.40%) |
| FY2020 | 12.0× | 38.82% |
| FY2019 | 8.7× | (28.33%) |
| FY2018 | 12.1× | (57.33%) |
| FY2017 | 28.3× | 67.30% |
| FY2016 | 16.9× | (25.82%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 14.9× | 23.64% |
| Mar 2026 | 12.1× | (13.71%) |
| Dec 2025 | 14.0× | 38.46% |
| Sep 2025 | 10.1× | (14.88%) |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| SNY Sanofi compare | 7.9× |
| BMY Bristol Myers Squibb Company compare | 13.5× |
| GSK GSK PLC Sponsored ADR compare | 15.6× |
| BIIB Biogen Inc. | 15.9× |
| GILD Gilead Sciences, Inc. compare | 16.8× |
| PFE Pfizer Inc. compare | 21.6× |
| NVO Novo Nordisk A/S compare | 24.5× |
| AMGN Amgen Inc. compare | 28.4× |
| AZN AstraZeneca PLC compare | 44.9× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement